The extensive clinical program for Libtayo is focused on difficult-to-treat cancers. Libtayo is currently being investigated in trials as a monotherapy, as well as in combination with either ...

A phase 1/2 trial is examining the novel agent, SNS-101, with or without Libtayo for the treatment of patients with advanced solid cancers. The first patient has been dosed in a phase 1/2 clinical ...

in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer (NSCLC) in Immuneering’s ongoing Phase 2a clinical trial of IMM-1-104 in advanced ...

dose-finding clinical trial, was designed to evaluate the agent's anti-tumor activity in combination with PD-(L)1 inhibition. The investigation will determine whether administering low doses of THIO ...

Treatment with THIO followed by cemiplimab (Libtayo ®) has been generally ... progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ...

Dr Israel Lowy, senior vice president of translational and clinical sciences in ... and vice-chair of the Trial Steering Committee, commented: “Libtayo is an important advancement for patients ...

or visit our clinical trials website. Libtayo is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary ...

Both monotherapy arms showed clinical activity ... The partners agreed to jointly fund a phase 2 trial of BNT111 and Libtayo. Each company retained full commercial rights to its molecule.

The extensive clinical program for Libtayo is focused on difficult-to-treat cancers. Libtayo is currently being investigated in trials as a monotherapy, as well as in combination with either ...

Arm 1 will administer Libtayo on day 5 ... About THIO-101, a Phase 2 Clinical Trial THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed ...